Biomaterials Research (생체재료학회지)

Korean Society for Biomaterials (한국생체재료학회)
권호 표지
DOI QR코드

DOI QR Code

Theranostics and contrast agents for magnetic resonance imaging

  • Jeong, Yohan (Department of Biotechnology, Center for Photomedicine, The Catholic University of Korea) ;
  • Hwang, Hee Sook (Department of Biotechnology, Center for Photomedicine, The Catholic University of Korea) ;
  • Na, Kun (Department of Biotechnology, Center for Photomedicine, The Catholic University of Korea)
  • Received : 2018.05.08
  • Accepted : 2018.07.18
  • Published : 2018.09.30
⟨ Previous Next ⟩

Abstract

Background: Magnetic resonance imaging is one of the diagnostic tools that uses magnetic particles as contrast agents. It is noninvasive methodology which provides excellent spatial resolution. Although magnetic resonance imaging offers great temporal and spatial resolution and rapid in vivo images acquisition, it is less sensitive than other methodologies for small tissue lesions, molecular activity or cellular activities. Thus, there is a desire to develop contrast agents with higher efficiency. Contrast agents are known to shorten both T1 and T2. Gadolinium based contrast agents are examples of T1 agents and iron oxide contrast agents are examples of T2 agents. In order to develop high relaxivity agents, gadolinium or iron oxide-based contrast agents can be synthesized via conjugation with targeting ligands or functional moiety for specific interaction and achieve accumulation of contrast agents at disease sites. Main body: This review discusses the principles of magnetic resonance imaging and recent efforts focused on specificity of contrast agents on specific organs such as liver, blood, lymph nodes, atherosclerotic plaque, and tumor. Furthermore, we will discuss the combination of theranostic such as contrast agent and drug, contrast agent and thermal therapy, contrast agent and photodynamic therapy, and neutron capture therapy, which can provide for cancer diagnosis and therapeutics. Conclusion: These applications of magnetic resonance contrast agents demonstrate the usefulness of theranostic agents for diagnosis and treatment.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65:500-16.
  2. Sumer B, Gao J, Theranostic nanomedicine for cancer. 2008.
  3. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu L-Y, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. J Am Coll Cardiol Img. 2012;5:596-603.
  4. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, Hill MD, Patronas N, Latour L, Warach S. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007;369:293-8.
  5. Yao L, Lee J. Occult intraosseous fracture: detection with MR imaging. Radiology. 1988;167:749-51.
  6. Chen XS. Introducing theranostics journal-from the editor-in-chief. Theranostics. 2011;1:1.
  7. Conde J, Bao C, Cui D, Baptista PV, Tian F. Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics. J Control Release. 2014;183:87-93.
  8. Gautam A, Kapoor P, Chaudhary K, Kumar R, Raghava G, Consortium SDD. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics. Curr Med Chem. 2014;21:2367-91.
  9. Shigdar S, Macdonald J, O'Connor M, Wang T, Xiang D, Al Shamaileh H, Qiao L, Wei M, Zhou S-F, Zhu Y. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors. 2013;13:13624-37.
  10. Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou S-F, Kong L, Li Y, Pu C, Duan W. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015;5:23.
  11. Shrestha R, Elsabahy M, Luehmann H, Samarajeewa S, Florez-Malaver S, Lee NS, Welch MJ, Liu Y, Wooley KL. Hierarchically assembled theranostic nanostructures for siRNA delivery and imaging applications. J Am Chem Soc. 2012;134:17362-5.
  12. Liu Y, Feng L, Liu T, Zhang L, Yao Y, Yu D, Wang L, Zhang N. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6:3231-42.
  13. Moon GD, Choi S-W, Cai X, Li W, Cho EC, Jeong U, Wang LV, Xia Y. A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc. 2011;133:4762-5.
  14. Liu P, Yue C, Shi B, Gao G, Li M, Wang B, Ma Y, Cai L. Dextran based sensitive theranostic nanoparticles for near-infrared imaging and photothermal therapy in vitro. Chem Commun. 2013;49:6143-5.
  15. Zhang Z, Wang J, Chen C. Gold nanorods based platforms for lightmediated theranostics. Theranostics. 2013;3:223.
  16. Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med. 2012;53:345-8.
  17. Ogawa S, Lee T-M, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci. 1990;87:9868-72.
  18. Selskog P, Heiberg E, Ebbers T, Wigstrom L, Karlsson M. Kinematics of the heart: strain-rate imaging from time-resolved three-dimensional phase contrast MRI. IEEE Trans Med Imaging. 2002;21:1105-9.
  19. Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain. 2002;125:812-22.
  20. Moser T, Dosch J-C, Moussaoui A, Dietemann J-L. Wrist ligament tears: evaluation of MRI and combined MDCT and MR arthrography. Am J Roentgenol. 2007;188:1278-86.
  21. Bashir A, Gray M, Hartke J, Burstein D. Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med. 1999;41:857-65.
  22. Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerth EW, Chen ZG, Platt S. Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics. 2012;2:113.
  23. Brown RW, Haacke EM, Cheng Y-CN, Thompson MR, Venkatesan R. Resonance imaging: physical principles and sequence design: second edition. Wiley Blackwell; 2014. https://doi.org/10.1002/9781118633953.
  24. Carreira GC, Gemeinhardt O, Beyersdorff D, Schnorr J, Taupitz M, Ludemann L. Effects of water exchange on MRI-based determination of relative blood volume using an inversion-prepared gradient echo sequence and a blood pool contrast medium. Magn Reson Imaging. 2009;27:360-9.
  25. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21:2133-48.
  26. Bloembergen N, Morgan L. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J Chem Phys. 1961;34:842-50.
  27. Bloembergen N. Proton relaxation times in paramagnetic solutions. J Chem Phys. 1957;27:572-3.
  28. Solomon I, Bloembergen N. Nuclear magnetic interactions in the HF molecule. J Chem Phys. 1956;25:261-6.
  29. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident noninvasive diagnosis of focal liver lesions. Eur Radiol. 2009;19:342-57.
  30. Yim H, Yang S-G, Jeon YS, Park IS, Kim M, Lee DH, Bae YH, Na K. The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI. Biomaterials. 2011;32:5187-94.
  31. Toft KG, Hustvedt S, Grant D, Martinsen I, Gordon P, Friisk G, Korsmo A, Skotland T. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 1997;38:677-89.
  32. Elizondo G, Fretz C, Stark D, Rocklage S, Quay S, Worah D, Tsang Y, Chen M, Ferrucci J. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology. 1991;178:73-8.
  33. Rummeny E, Ehrenheim C, Gehl H, Hamm B, Laniado M, Lodemann K, Schmiedel E, Steudel A, Vogl TG. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors: results of clinical phase II trials in Germany including 141 patients. Investig Radiol. 1991;26:S142-S5.
  34. de Haen C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR- rats. Acad Radiol. 1996;3:S452-S4.
  35. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Investig Radiol. 1993;28:753-61.
  36. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol. 1998;5:S86-S9.
  37. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-7.
  38. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559-78.
  39. Mohs AM, Lu Z-R. Gadolinium (III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opinion on Drug Delivery. 2007;4:149-64.
  40. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM. Molecular imaging of angiogenesis in early-stage atherosclerosis with ${\alpha}v{\beta}3$-integrin-targeted nanoparticles. Circulation. 2003;108:2270-4.
  41. Li KC, Bednarski MD. Vascular-targeted molecular imaging using functionalized polymerized vesicles. J Magn Reson Imaging. 2002;16:388-93.
  42. Mohs AM, Wang X, Goodrich KC, Zong Y, Parker DL, Lu Z-R. PEG-g-poly (GdDTPA-co-L-cystine): a biodegradable macromolecular blood pool contrast agent for MR imaging. Bioconjug Chem. 2004;15:1424-30.
  43. de Haen C, Anelli PL, Lorusso V, Morisetti A, Maggioni F, Zheng J, Uggeri F, Cavagna FM. Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. Investig Radiol. 2006;41:279-91.
  44. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging. 2001;14:237-42.
  45. Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP. MRI monitoring of $Avastin^{TM}$ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging. 2004;20:865-73.
  46. Misselwitz B. MR contrast agents in lymph node imaging. Eur J Radiol. 2006; 58:375-82.
  47. Suga K, Yuan Y, Ogasawara N, Okada M, Matsunaga N. Localization of breast sentinel lymph nodes by MR lymphography with a conventional gadolinium contrast agent. Acta Radiol. 2003;44:35-42.
  48. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20:1177-8.
  49. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-54.
  50. Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JGS, Barazza A, Ma Y, Fisher EA, Fayad ZA. An ApoA-I mimetic peptide high-density-lipoproteinbased MRI contrast agent for atherosclerotic plaque composition detection. Small. 2008;4:1437-44.
  51. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006;6:2220-4.
  52. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126:16316-7.
  53. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class a amphipathic helical peptide. J Lipid Res. 2001;42:1096-104.
  54. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008;3:233-42.
  55. Rijpkema M, Kaanders JH, Joosten F, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging. 2001;14:457-63.
  56. Rhyner MN, Smith AM, Gao X, Mao H, Yang L, Nie S, Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. 2006.
  57. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-21.
  58. Cai Q-Y, Kim SH, Choi KS, Kim SY, Byun SJ, Kim KW, Park SH, Juhng SK, Yoon K-H. Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray computed tomography in mice. Investig Radiol. 2007;42:797-806.
  59. Aime S, Cabella C, Colombatto S, Geninatti Crich S, Gianolio E, Maggioni F. Insights into the use of paramagnetic Gd (III) complexes in MR-molecular imaging investigations. J Magn Reson Imaging. 2002;16:394-406.
  60. Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R. The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers. Anticancer Res. 2005;25:3665-70.
  61. Kobayashi H, Kawamoto S, Jo S-K, Bryant HL, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 2003;14:388-94.
  62. Morawski AM, Lanza GA, Wickline SA. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol. 2005;16:89-92.
  63. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;63:2723-7.
  64. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001;7:4008-12.
  65. Kim KS, Park W, Hu J, Bae YH, Na K. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. Biomaterials. 2014;35:337-43.
  66. Anbarasu M, Anandan M, Chinnasamy E, Gopinath V, Balamurugan K. Synthesis and characterization of polyethylene glycol (PEG) coated Fe3O4 nanoparticles by chemical co-precipitation method for biomedical applications. Spectrochim Acta A Mol Biomol Spectrosc. 2015;135:536-9.
  67. Saraswathy A, Nazeer SS, Nimi N, Arumugam S, Shenoy SJ, Jayasree RS. Synthesis and characterization of dextran stabilized superparamagnetic iron oxide nanoparticles for in vivo MR imaging of liver fibrosis. Carbohydr Polym. 2014;101:760-8.
  68. Castello J, Gallardo M, Busquets MA, Estelrich J. Chitosan (or alginate)-coated iron oxide nanoparticles: a comparative study. Colloids Surf A Physicochem Eng Asp. 2015;468:151-8.
  69. Yoon GJ, Lee SY, Lee SB, Park GY, Choi JH. Synthesis of Iron oxide/gold composite nanoparticles using Polyethyleneimine as a polymeric active stabilizer for development of a dual imaging probe. Nanomaterials. 2018;8(5):300.
  70. Zhang M, Xing L, Ke H, He Y-J, Cui P-F, Zhu Y, Jiang G, Qiao J-B, Lu N, Chen H. MnO2-Based Nanoplatform Serves as Drug Vehicle and MRI Contrast Agent for Cancer Theranostics. ACS Appl Mater Interfaces. 2017;9:11337-44.
  71. Sundaresan V, Menon JU, Rahimi M, Nguyen KT, Wadajkar AS. Dualresponsive polymer-coated iron oxide nanoparticles for drug delivery and imaging applications. Int J Pharm. 2014;466:1-7.
  72. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008;2:889-96.
  73. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin S-F, Sherry AD, Boothman DA, Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006;6:2427-30.
  74. Fan C-H, Ting C-Y, Lin H-J, Wang C-H, Liu H-L, Yen T-C, Yeh C-K. SPIOconjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials. 2013;34:3706-15.
  75. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15:171-85.
  76. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052-63.
  77. Lin G, Zhu W, Yang L, Wu J, Lin B, Xu Y, Cheng Z, Xia C, Gong Q, Song B. Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells. Biomaterials. 2014;35:9495-507.
  78. Maeng JH, Lee D-H, Jung KH, Bae Y-H, Park I-S, Jeong S, Jeon Y-S, Shim C-K, Kim W, Kim J. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials. 2010;31:4995-5006.
  79. Klein PP: Apparatus for localized heat and cold therapy. Google Patents;1990.
  80. Zhou XD, Tang ZY. Cryotherapy for primary liver cancer. In: Seminars in surgical oncology: Wiley Online Library. 1998;14(2):171-4. https://doi.org/10.1002/(SICI)1098-2388(199803)14:2<171::AID-SSU9>3.0.CO;2-2
  81. Vergnon J, Huber R, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J. 2006;28:200-18.
  82. Yan J-F, Liu J. Nanocryosurgery and its mechanisms for enhancing freezing efficiency of tumor tissues. Nanomedicine. 2008;4:79-87.
  83. Svaasand LO, Boerslid T, Oeveraasen M. Thermal and optical properties of living tissue: application to laser-induced hyperthermia. Lasers Surg Med. 1985;5:589-602.
  84. Terentyuk GS, Maslyakova GN, Suleymanova LV, Khlebtsov NG, Khlebtsov BN, Akchurin GG, Maksimova IL, Tuchin VV. Laser-induced tissue hyperthermia mediated by gold nanoparticles: toward cancer phototherapy. J Biomed Opt. 2009;14:021016.
  85. Marmor JB, Hahn GM. Ultrasound heating in previously irradiated sitest. International Journal of Radiation Oncology Biology Physics. 1978;4:1029-32.
  86. Marmor JB, Pounds D, Postic TB, Hahn GM. Treatment of superficial human neoplasms by local hyperthermia induced by ultrasound. Cancer. 1979;43:188-97.
  87. Diederich CJ, Hynynen K. Ultrasound technology for hyperthermia. Ultrasound Med Biol. 1999;25:871-87.
  88. Jordan A, Scholz R, Wust P, Fahling H, Felix R. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater. 1999; 201:413-9.
  89. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater. 2002;252:370-4.
  90. Hu D-H, Sheng Z-H, Zhang P-F, Yang D-Z, Liu S-H, Gong P, Gao D-Y, Fang S-T, Ma Y-F, Cai L-T. Hybrid gold-gadolinium nanoclusters for tumor-targeted NIRF/CT/MRI triple-modal imaging in vivo. Nanoscale. 2013;5:1624-8.
  91. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng J-X, Wei A, Hyperthermic effects of gold nanorods on tumor cells. 2007.
  92. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neuro-Oncol. 2006;78:7-14.
  93. Hilger I, Hergt R, Kaiser WA. Towards breast cancer treatment by magnetic heating. J Magn Magn Mater. 2005;293:314-9.
  94. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldofner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and threedimensional temperature distribution. Eur Urol. 2007;52:1653-62.
  95. Yan S, Zhang D, Gu N, Zheng J, Ding A, Wang Z, Xing B, Ma M, Zhang Y. Therapeutic effect of Fe2O3 nanoparticles combined with magnetic fluid hyperthermia on cultured liver cancer cells and xenograft liver cancers. J Nanosci Nanotechnol. 2005;5:1185-92.
  96. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252-65.
  97. Moroz P, Jones SK, Winter J, Gray BN. Targeting liver tumors with hyperthermia: ferromagnetic embolization in a rabbit liver tumor model. J Surg Oncol. 2001;78:22-9.
  98. Lin J, Wang S, Huang P, Wang Z, Chen S, Niu G, Li W, He J, Cui D, Lu G. Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano. 2013;7:5320-9.
  99. Han Y, An Y, Jia G, Wang X, He C, Ding Y, Tang Q. Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma. Nanoscale. 2018;10:6511-23.
  100. Skupin-Mrugalska P, Sobotta L, Warowicka A, Wereszczynska B, Zalewski T, Gierlich P, Jarek M, Nowaczyk G, Kempka M, Gapinski J. Theranostic liposomes as a bimodal carrier for magnetic resonance imaging contrast agent and photosensitizer. J Inorg Biochem. 2018;180:1-14.
  101. Gahbauer R, Gupta N, Blue T, Goodman J, Barth R, Grecula J, Soloway A, Sauerwein W, Wambersie A. Boron neutron capture therapy: principles and potential. In: Fast Neutrons and High-LET Particles in Cancer Therapy. Berlin, Heidelberg: Springer; 1998. p. 183-209. https://doi.org/10.1007/978-3-642-78774-4_12.
  102. Enger SA, Giusti V, Fortin M-A, Lundqvist H, af Rosenschold PM. Dosimetry for gadolinium neutron capture therapy (GdNCT). Radiat Meas. 2013;59:233-40.
  103. Salt C, Lennox AJ, Takagaki M, Maguire JA, Hosmane NS. Boron and gadolinium neutron capture therapy. Russ Chem Bull. 2004;53:1871-88.
  104. Dewi N, Mi P, Yanagie H, Sakurai Y, Morishita Y, Yanagawa M, Nakagawa T, Shinohara A, Matsukawa T, Yokoyama K. In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent. J Cancer Res Clin Oncol. 2016;142:767-75.
  105. Shikata F, Tokumitsu H, Ichikawa H, Fukumori Y. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur J Pharm Biopharm. 2002;53:57-63.
  106. Tokumitsu H, Hiratsuka J, Sakurai Y, Kobayashi T, Ichikawa H, Fukumori Y. Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett. 2000;150:177-82.
  107. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res. 1999;16:1830-5.
  108. Shih JLA, Brugger RM. Gadolinium as a neutron capture therapy agent. Med Phys. 1992;19:733-44.
  109. Balafar MA, Ramli AR, Saripan MI, Mashohor S. Review of brain MRI image segmentation methods. Artif Intell Rev. 2010;33:261-74.
  110. Schmitz BL, Aschoff AJ, Hoffmann MH, Gron G. Advantages and pitfalls in 3T MR brain imaging: a pictorial review. Am J Neuroradiol. 2005;26:2229-37.
  111. Verbeeten KM, Hermann KL, Hasselqvist M, Lausten GS, Joergensen P, Jensen CM, Thomsen HS. The advantages of MRI in the detection of occult hip fractures. Eur Radiol. 2005;15:165-9.
  112. Wang G, Yu H, De Man B. An outlook on x-ray CT research and development. Med Phys. 2008;35:1051-64.
  113. Fitzgerald R. Phase-sensitive x-ray imaging. Phys Today. 2000;53:23-6.
  114. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Wurker M, Heiss W-D. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med. 1994;35:2011-8.
  115. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193-207.
  116. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87:II56-65.
  117. Van Montfoort JE, Stieger B, Meijer DK, Weinmann H-J, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153-7.
  118. Herborn CU, Honold E, Wolf M, Kemper J, Kinner S, Adam G, Barkhausen J. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Investig Radiol. 2007;42:58-62.
  119. Tanaka H, Tanigawa T, Suzuki M, Otsuka K, Inafuku S. Effects of MRI contrast agents ($Omniscan^{TM}$) on vestibular end organs. Acta Otolaryngol. 2010;130:17-24.
  120. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Investig Radiol. 1998;33:798-809.
  121. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology. 1995;196:439-43.
  122. Runge VM, Kirsch JE, Burke VJ, Price AC, Nelson KL, Thomas GS, Dean BL, Lee C. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging. 1992;2:9-18.
  123. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008;117:629-37.
  124. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann H-J, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Investig Radiol. 1994;29:709-15.
  125. Jordan R, Mintz R. Fatal reaction to gadopentetate dimeglumine. Am J Roentgenol. 1995;164:743-4.
  126. Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag. 2008;4:1.
  127. Hompland T, Ellingsen C, Rofstad EK. Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure. BMC Cancer. 2012;12:544.
  128. Bjornerud A, Johansson LO, Ahlstrom H. Pre-clinical results with $Clariscan^{TM}$(NC100150 injection); experience from different disease models. MAGMA. 2001;12:99-103.
  129. Clement O, Siauve N, Cuenod C-A, Frija G. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top Magn Reson Imaging. 1998;9:167-82.
  130. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications a review. J Drug Target. 1998;6:167-74.
  131. Sigal R, Vogl T, Casselman J, Moulin G, Veillon F, Hermans R, Dubrulle F, Viala J, Bosq J, Mack M. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR)-results of a phase-III multicenter clinical trial. Eur Radiol. 2002;12:1104-13.
  132. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RESspecific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266-76.

Cited by

  1. Controlled Anchoring of Iron Oxide Nanoparticles on Polymeric Nanofibers: Easy Access to Core@Shell Organic-Inorganic Nanocomposites for Magneto-Scaffolds vol.11, pp.9, 2019, https://doi.org/10.1021/acsami.8b19099
  2. Polymetallic Complexes for Applications as Photosensitisers in Anticancer Photodynamic Therapy vol.3, pp.1, 2018, https://doi.org/10.1002/adtp.201900139
  3. In vivo Imaging Technologies to Monitor the Immune System vol.11, pp.None, 2018, https://doi.org/10.3389/fimmu.2020.01067
  4. Magnetic Nanomaterials as Contrast Agents for MRI vol.13, pp.11, 2020, https://doi.org/10.3390/ma13112586
  5. An advanced micelle-based biodegradable HPMA polymer-gadolinium contrast agent for MR imaging of murine vasculatures and tumors vol.11, pp.39, 2018, https://doi.org/10.1039/d0py01133a
  6. Magnetic domains orientation in (Fe3O4/γ-Fe2O3) nanoparticles coated by Gadolinium-diethylenetriaminepentaacetic acid (Gd3+-DTPA) vol.2, pp.2, 2018, https://doi.org/10.1088/2632-959x/ac0107
  7. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM) vol.18, pp.7, 2018, https://doi.org/10.1080/17425247.2021.1873273
  8. Iron-Quercetin Complex Preconditioning of Human Peripheral Blood Mononuclear Cells Accelerates Angiogenic and Fibroblast Migration: Implications for Wound Healing vol.22, pp.16, 2021, https://doi.org/10.3390/ijms22168851
  9. Fascinating MXene nanomaterials: emerging opportunities in the biomedical field vol.9, pp.16, 2018, https://doi.org/10.1039/d1bm00526j
  10. Cutting-edge development in dendritic polymeric materials for biomedical and energy applications vol.160, pp.None, 2018, https://doi.org/10.1016/j.eurpolymj.2021.110770
  11. Magnetic Resonance Imaging-Guided Multi-Stimulus-Responsive Drug Delivery Strategy for Personalized and Precise Cancer Treatment vol.13, pp.43, 2018, https://doi.org/10.1021/acsami.1c13853
  12. Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review vol.13, pp.12, 2021, https://doi.org/10.3390/pharmaceutics13122000